Infectious Disease· Topic 7.9 HIV transmission, prevention, and prophylaxis· 7.9.5

Prevention of opportunistic infections in HIV

Opportunistic infection prophylaxis in HIV is a CD4-stratified framework: Pneumocystis prophylaxis at CD4 <200/mcL, Toxoplasma prophylaxis at CD4 <100/mcL in seropositive patients, and MAC prophylaxis at CD4 <50/mcL, each with a defined drug, dose, and CD4-recovery threshold for stopping. Antiretroviral therapy, started regardless of CD4 count, is the definitive prevention strategy and can make primary MAC prophylaxis unnecessary when started promptly.

10 min read2 practice questions7 key factsSubscriber article
  • Topic review
    The full article, organized the way the exam asks it.
  • ABIM-format MCQs
    Vignettes with an explanation for every wrong answer.
  • Key facts
    The numbers and thresholds worth memorizing, up front.
  • AI tutor
    MedBrain answers the question you're stuck on.

What this article covers

  • Overview

    This is a CD4-count-stratified prophylaxis framework, not a single disease: each opportunistic infection (OI) becomes a prophylaxis target once CD4 count crosses its own threshold.

  • Epidemiology

    Before prophylaxis and ART, opportunistic infections were the dominant cause of AIDS-related death; incidence of every OI here has fallen sharply in the ART era.

  • Risk factors

    CD4 count below the OI-specific threshold is the dominant risk factor for every entity in this framework, more than any other single variable.

  • Pathophysiology

    Progressive CD4 T-cell depletion removes cell-mediated immune surveillance in a graded fashion, so each pathogen re-emerges once the surveillance it depends on is lost, producing the characteristic thresholds rather than a single cliff.

  • Clinical features

    The framework is organized by which CD4-defined risk tier a patient occupies, and that tier determines which prophylaxis applies; recognizing the tier is the practical equivalent of knowing what to prescribe.

  • Differential diagnosis

    Bacterial community-acquired pneumonia: more likely than Pneumocystis at any CD4 count; distinguished by productive cough, lobar consolidation, and rapid response to beta-lactam therapy.

  • Diagnosis

    This is not a single-disease diagnosis; the applicable prophylaxis is established by matching a baseline CD4 cell count and percentage plus targeted serologic results against the CD4-threshold triggers above, reassessed at each CD4 recheck.

  • Management

    First, start ART in every patient regardless of CD4 count, as soon as the patient is ready; this single intervention prevents progression through every threshold below and, over time, allows every prophylactic regimen to be discontinued.

  • Complications

    Breakthrough opportunistic infection from a missed threshold or premature discontinuation, the most preventable complication here.

  • Prognosis

    ART reverses the framework from the top down: durable suppression allows discontinuation in sequence, Pneumocystis and toxoplasmosis first (CD4 past 200/mcL), then MAC (CD4 past 100/mcL).

  • Prevention

    Vaccinate at diagnosis, independent of CD4 count: 13-valent pneumococcal conjugate vaccine, then 23-valent pneumococcal polysaccharide vaccine at least 8 weeks later, with a polysaccharide booster at…

Read the whole article

Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.